Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Scibase Holding

0,38

 

SEK

 

-4,76 %

Mindre end 1K følgere

SCIB

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Ownership
Investor consensus
Sammenligne
-4,76%
-0,26%
-1,55%
-7,32%
-2,56%
+18,75%
-90,9%
-82,52%
-98,65%

SciBase Holding is a global medical technology group specialized in diagnostics and prevention in dermatology. The company develops, produces and commercializes Nevisense, a patient-centered platform that combines AI (artificial intelligence) with EIS technology to enable early detection and intervention of skin cancer and other skin diseases. Nevisense is based on over 20 years of research at Karolinska Institutet, the headquarters are in Stockholm.

Læs mere
Markedsværdi
128,55 mio. SEK
Aktieomsætning
17,86 t SEK
Omsætning
29,71 mio.
EBIT %
-226,09 %
P/E
-
Udbytteafkast, %
-
Latest research

Seneste analyse

Released: 02.12.2024

Seneste omfattende analyse

Released: 01.02.2024

Finanskalender
19.8
2025

Delårsrapport Q2'25

7.11
2025

Delårsrapport Q3'25

Alle
Analyse
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper
Pressemeddelelse27.5.2025, 11.00

SciBase reaches milestone with over 300,000 patients tested with Nevisense

Scibase Holding
Selskabsmeddelelse23.5.2025, 13.00

SciBase publishes the Annual report for 2024

Scibase Holding
Pressemeddelelse20.5.2025, 20.29

Redeye: Scibase Q1 - Laying the groundwork for US expansion

Scibase Holding

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Selskabsmeddelelse14.5.2025, 13.00

SciBase: Notice to attend the annual general meeting in Scibase Holding AB (publ)

Scibase Holding
Selskabsmeddelelse13.5.2025, 06.00

SciBase: Interim report

Scibase Holding
Pressemeddelelse11.4.2025, 13.30

SciBase launches next generation Nevisense

Scibase Holding
Pressemeddelelse26.2.2025, 08.18

Redeye: SciBase Q4’2024 - Investing in US growth

Scibase Holding
Selskabsmeddelelse25.2.2025, 07.00

SciBase: Year-end report

Scibase Holding
Pressemeddelelse21.2.2025, 07.00

SciBase: New study shows significant improved clinical accuracy with Nevisense for both US and German dermatologists

Scibase Holding
Pressemeddelelse30.1.2025, 12.00

SciBase continues US expansion, on-boards Several US Dermatology Practices that Specialize in Skin Cancer Detection

Scibase Holding
Pressemeddelelse28.1.2025, 07.00

SciBase: New review article highlights Nevisense effectiveness in identifying malignant skin lesions

Scibase Holding
Selskabsmeddelelse27.1.2025, 07.00

SciBase: Recalculation of warrants of series TO 2 following rights issue

Scibase Holding
Pressemeddelelse23.1.2025, 15.30

SciBase: Nevisense (EIS) included in updated German (S1) imaging guidelines.

Scibase Holding
Selskabsmeddelelse14.1.2025, 17.00

SciBase announces final outcome of directed issue and rights issue

Scibase Holding
Selskabsmeddelelse13.1.2025, 19.00

SciBase announces outcome of directed issue and preliminary outcome of rights issue

Scibase Holding
Pressemeddelelse3.1.2025, 07.00

SciBase: The Mayo Clinic, the leading US hospital, will test Nevisense in Pilot

Scibase Holding
Pressemeddelelse27.12.2024, 07.00

Today the subscription period in SciBase rights issue begins

Scibase Holding
Pressemeddelelse20.12.2024, 12.15

SciBase letter from the CEO

Scibase Holding
Selskabsmeddelelse20.12.2024, 12.00

SciBase publishes prospectus

Scibase Holding
Selskabsmeddelelse13.12.2024, 10.00

Bulletin from the extraordinary general meeting in SciBase Holding AB (publ)

Scibase Holding
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team